Thiago Carvalho @cyrilpedia@social.cleverlibre.org

Aquatint & chine-collé with colours added through viscosity printing by @madparreira

https://madalenaparreira.com/Aquatints

#Prints #Printmaking #Print #artofinstagram #Aquatint
#Handmade #chinecollé #artmastodon

'25 de Abril sempre, diz Rui Rocha. Mas que demonstra ele saber sobre o 25 de Abril? Nada. O povo quis uma sociedade nova e confrontou as classes dominantes – banqueiros, industriais e latifundiários – pondo em causa o seu domínio, poder e propriedade. Se recuasse no tempo, nesta luta, de que lado estaria Rui Rocha? Não é difícil de adivinhar: os interesses económicos que defende e apregoa estavam no lado do fascismo e do colonialismo, nunca no do povo.'

https://www.publico.pt/2023/04/26/opiniao/opiniao/rui-rocha-lugarcomum-2047426

From "Albert and the Whale" by Philip Hoare.

#book #bookshelf

And a more recent piece by Asher Mullard for Nature

"A thumbs-up for tofersen from the US Food and Drug Administration would reinforce the agency’s shifting approach to neurological drugs."

https://www.nature.com/articles/d41586-023-01039-4?error=cookies_not_supported&code=8a22efab-f191-48b7-9013-703e307abaf7&utm_medium=Social&utm_campaign=nature&utm_source=Twitter#ref-CR2

Here's a link to the FDA's decision:

"FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS)."

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

The FDA has approved Biogen's ALS drug, Tofersen, an antisense oligo targeting SOD1. I wrote about this back in September in my Clinical Pipeline column as part of a shift towards approving drugs based on biomarkers without clear signs of clinical efficacy*.

https://www.nature.com/articles/d41591-022-00098-w

*You can have a look at the trial data in NEJM, in a study that concluded that "In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events."

https://lnkd.in/dwGMYGgh

#NatureMedicine #amyotrophiclateralsclerosis #drugdevelopment #pharma

From Andersen-Nissen et al, PNAS 2005.

"We map the site responsible for TLR5 evasion to amino acids 89-96 of the N-terminal D1 domain, which is centrally positioned within the previously defined TLR5 recognition site. Salmonella flagellin is strongly recognized by TLR5, but mutating residues 89-96 to the corresponding H. pylori flaA sequence abolishes TLR5 recognition and also destroys bacterial motility."

https://www.pnas.org/doi/full/10.1073/pnas.0502040102

'Flagella-driven motility is essential for the entry of H. pylori into the mucus layer and for maintaining a swimming reservoir in the mucus (Fig. 3). H. pylori has a unipolar bundle of rotating sheathed flagella, with filaments composed of two flagellin proteins that evade activating the innate immune system via TLR5 due to specific adaptation of their amino acid sequences'

#Helicobacter #InnateImmunity #HostPathogen

https://www.nature.com/articles/s41572-023-00431-8

"The European Commission is pressing ahead with a plan to cut the number of years of market exclusivity — the period before a drugmaker faces competition from generic manufacturers — from 10 to eight years, despite fierce opposition from the industry and concerns from larger countries that have greater access to medicines."

https://www.ft.com/content/ace93ce5-7baa-41c5-9f6b-2a01e64914e4

'The study, published Friday in JAMA Network Open, is the first to link a higher prevalence of Black doctors to longer life expectancy and lower mortality in Black populations.'

https://www.statnews.com/2023/04/14/black-doctors-primary-care-life-expectancy-mortality/